Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 53 of 315 for:    BENDAMUSTINE

Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting (FIL-BBV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02499627
Recruitment Status : Recruiting
First Posted : July 16, 2015
Last Update Posted : May 1, 2019
Sponsor:
Information provided by (Responsible Party):
Fondazione Italiana Linfomi ONLUS

Brief Summary:

This is a single-arm, open-label, multicenter, phase 2 clinical trial aimed at evaluating the efficacy and safety of the combination of bendamustine and brentuximab vedotin as a first salvage therapy in patients with relapsed or refractory Hodgkin's lymphoma or PTCL.

A total of 25 patients with PTCL, and 40 with Hodgkin's lymphoma are expected to be treated according to this treatment protocol.


Condition or disease Intervention/treatment Phase
Lymphatic Diseases Drug: Brentuximab Vedotin Drug: Bendamustine Phase 2

Detailed Description:
In the study, intravenous bendamustine will be administered at a dose of 90 mg/m2 on day 1 and 2 and brentuximab will be given intravenously at a total dose of 1.8 mg/kg on day 1 of each 21 days-based cycle, for 6 cycles. All patients achieving a CR can be considered eligible to peripheral blood stem cell mobilization (to be performed with granulocytecolony stimulating factor alone) and may proceed to an ASCT at any time after cycle 4.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 65 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study With Bendamustine Plus Brentuximab Vedotin in Hodgkin's Lymphoma and CD30+ Peripheral T-cell Lymphoma in First Salvage Setting: the BBV Regimen.
Study Start Date : October 2015
Estimated Primary Completion Date : October 2021
Estimated Study Completion Date : October 2021


Arm Intervention/treatment
Experimental: Bendamustine + Brentuximab for 6 cycles
Bendamustine 90 mg/m2 d1-2. Brentuximab vedotin 1.8 mg/kg d1.Every 21 days for 6 cycles.
Drug: Brentuximab Vedotin
Brentuximab will be given intravenously at a total dose of 1.8 mg/kg on day 1 of each 21 days-based cycle, for 6 cycles.
Other Name: SGN35

Drug: Bendamustine
Bendamustine will be administered at a dose of 90 mg/m2 on day 1 and 2 of each 21 days-based cycle, for 6 cycles.
Other Name: Levact




Primary Outcome Measures :
  1. Overall objective response rate (ORR). [ Time Frame: 1 year ]
    Proportion of patients in CR or PR


Secondary Outcome Measures :
  1. Duration of the response (DOR) [ Time Frame: 1 year ]
    Time from documentation of tumor response to disease progression

  2. Complete remission (CR) rate [ Time Frame: 1 year ]
    Proportion of patients in CR

  3. Progression-free survival (PFS) [ Time Frame: 1 year ]
    Time from study enrollment until disease progression or death

  4. Adverse Events [ Time Frame: 1 year ]
    The type, incidence, severity, seriousness, of adverse events and laboratory abnormalities observed during treatment and the assessment of any potential relationship to the study drugs.

  5. Overall survival (OS) [ Time Frame: 1 year ]
    Time from study enrollment until death from any cause


Other Outcome Measures:
  1. One-year event-free survival (EFS) [ Time Frame: 1 year ]
    Time from study enrollment to disease progression, death, or discontinuation of treatment for any reason (eg, toxicity, patient preference, or initiation of a new treatment without documented progression)

  2. B symptoms resolution rate (when documented at presentation) [ Time Frame: 1 year ]
    Proportion of patients with B symptoms at the end of study

  3. CD30 expression and the objective response [ Time Frame: 1 year ]
    Correlation between the CD30 expression and the objective response obtained



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria for patients with classical Hodgkin's lymphoma:

  1. Patients with primary refractory disease after one previous line of therapy or at first relapse after one previous line of therapy. Patients must have completed any prior treatment with radiation, chemotherapy, biologics, immunotherapy and/or other investigational agents at least 4 weeks prior to the first BBV dose
  2. Histologically-confirmed CD30+ disease (IHC BerH2 antibody)
  3. Age from 18 to 60 years.
  4. Fluorodeoxyglucose (FDG)-avid and measurable disease (lymph nodes must have long axis of 1.5 cm regardless of short axis or long axis 1.1 to 1.5 and short axis > 1.0 cm) as documented by both PET and CT.
  5. An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  6. The following required baseline laboratory data: absolute neutrophil count (ANC) ≥ 1500/μL, unless known marrow involvement due to disease, platelets ≥ 75,000/μL, unless known marrow involvement due to disease, bilirubin ≤ 1.5 x upper limit of normal (ULN) or ≤ 3 x ULN for patients with Gilbert's disease, serum creatinine ≤ 1.5 X ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 X ULN.
  7. Serum Albumin ≥ 3 g/dL.
  8. Females of childbearing potential must have a negative serum or urine β-hCG pregnancy test result within 7 days prior to the first dose of therapy. Females of non-childbearing potential are those who are postmenopausal for more than 1 year or who have had a bilateral tubal ligation or hysterectomy.
  9. Both females of childbearing potential and males who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for at least 6 months following the last dose of study drug.
  10. Male patients, even if surgically sterilized (i.e., post vasectomy), who:

    1. Agree to practice effective barrier contraception during the entire study treatment period and through 6 months after the last dose of the study drug, or
    2. Agree to completely abstain from heterosexual intercourse.
  11. Patients must provide written informed consent

Exclusion criteria for patients with classical Hodgkin's lymphoma:

  1. Previous treatment with bendamustine or brentuximab vedotin.
  2. Prior autologous stem cell transplant.
  3. Known history of any of the following cardiovascular conditions: myocardial infarction within 2 years of study entry; NYHA class III or IV heart failure; cardiac arrhythmias; angina; any electrocardiographic evidence of acute ischemia or conduction system abnormalities; recent evidence (within 6 months before the first dose of study drug) of a left-ventricular ejection fraction < 50%.
  4. History of another primary malignancy for within 3 years of study entry (the following are exempt from the 3-year limit: non-melanoma skin cancer, curatively treated localized prostate cancer and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on PAP smear).
  5. Known cerebral/meningeal disease (HL or any other etiology) or testicular involvement.
  6. Signs or symptoms of progressive multifocal leukoencephalopathy (PML).
  7. Pre-existing Peripheral Neuropathy ≥ 2.
  8. Any active systemic viral, bacterial, or fungal infection requiring treatment with antimicrobial therapy within 2 weeks prior to the first dose of therapy.
  9. Current therapy with other systemic anti-neoplastic or investigational agents.
  10. Therapy with corticosteroids at greater than or equal to 20 mg/day prednisone equivalent within 1 week prior to the first dose of therapy.
  11. Women who are pregnant or breastfeeding.
  12. Patients with a known hypersensitivity to recombinant proteins, murine proteins, or any excipient contained in the drug formulation of brentuximab vedotin and to bendamustine.
  13. HIV positive.
  14. HCV positive.
  15. HBsAg positive; HBsAg negative patients with anti-HBcAg positive can be enrolled if HBV DNA is negative and antiviral treatment with Lamivudine or Tenofir is provided.
  16. Active varicella zoster virus (VZV) infection; previously infected patients is accepted only with concomitant treatment with Valacyclovir or Acyclovir.
  17. Patients with dementia or altered mental state that would preclude the understanding and rendering of informed consent.

Inclusion criteria for patients with peripheral T-cell lymphomas:

  1. Patients with refractory or relapsed PTCL regardless of the number of prior therapy lines. Patients must have completed any prior treatment with radiation, chemotherapy, biologics, immunotherapy and/or other investigational agents at least 4 weeks prior to the first dose of therapy.
  2. Signed written informed consent.
  3. Age from 18 to 60 years.
  4. Histologically confirmed diagnosis of PTCL, i.e. PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic T cell lymphoma (AITL) and transformed mycosis fungoides according to the World Health Organization (WHO) 2008 classification.
  5. Histologically confirmed CD30+ PTCL (IHC BerH2 antibody).
  6. Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 1 at study entry.
  7. At least one site of measurable disease in two dimensions by computed tomography. Both nodal and extranodal sites will be taken into consideration (lymph nodes must have long axis of 1.5 cm regardless of short axis or long axis 1.1 to 1.5 cm and short axis > 1.0 cm).
  8. Hematology values within the following limits:

    1. absolute neutrophil count (ANC) ≥ 1500/mm3 independent of growth factor support;
    2. platelets ≥ 75,000/mm3 or ≥ 50,000/mm3 if bone marrow involvement is independent of transfusion support;
    3. hemoglobin level ≥ 8 g/dL.
  9. Biochemical values within the following limits:

    1. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x upper limit of normal (ULN);
    2. total bilirubin < 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or has a non-hepatic origin);
    3. serum creatinine ≤ 2 x ULN;
    4. serum albumin ≥ 3 g/dL.
  10. Women of childbearing potential must have a negative pregnancy test within 7 days of receiving study medication and must agree to use effective contraception, defined as: oral contraceptives, double barrier method or practice true abstinence from sexual intercourse during the study and for at least 6 months after the last dose of study drug.
  11. Male subjects and their female partners of childbearing potential must be willing to use an appropriate method of contraception or practice true abstinence from sexual intercourse during the study and for at least 6 months after the last dose of study drug.

Exclusion criteria for patients with peripheral T-cell lymphomas:

  1. Diagnosis of cutaneous T-cell lymphoma, anaplastic large-cell lymphoma (ALCL), mycosis fungoides or Sézary Syndrome.
  2. Previous treatment with bendamustine or brentuximab vedotin.
  3. Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin and to bendamustine.
  4. Any serious active disease or co-morbid medical condition (according to investigator's decision).
  5. Prior history of malignancies other than lymphoma (except for a history of a complete resection for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for ≥ 3 years.
  6. Pre-existing peripheral neuropathy grade ≥ 2.
  7. Signs or symptoms of progressive multifocal leukoencephalopathy (PML).
  8. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
  9. Pregnant or lactating females or men or women of childbearing potential not willing to use an adequate method of birth control for the duration of the study or a positive pregnancy test on day 1 before first dose of study drug.
  10. Central nervous system disease (meningeal and/or brain involvement by lymphoma) or testicular involvement.
  11. History of clinically relevant liver or renal insufficiency; significant pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances.
  12. Known history of any of the following cardiovascular conditions: myocardial infarction within 2 years of study entry; NYHA class III or IV heart failure; cardiac arrhythmias; angina; any electrocardiographic evidence of acute ischemia or conduction system abnormalities; recent evidence (within 6 months before the first dose of study drug) of a left-ventricular ejection fraction < 50%.
  13. Active systemic, viral, bacterial, or fungal infection requiring systemic antibiotics within 2 weeks prior to first dose of study drug.
  14. HIV positive.
  15. HCV positive.
  16. HBsAg positive; HBsAg negative patients with anti-HBcAg positive can be enrolled if HBV DNA is negative and antiviral treatment with Lamivudine or Tenofir is provided.
  17. Active varicella zoster virus (VZV) infection; previously infected patients is accepted only with concomitant treatment with Valacyclovir or Acyclovir.
  18. Prior allogeneic stem cell transplant
  19. Patients with dementia or altered mental state that would preclude the understanding and rendering of informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02499627


Contacts
Layout table for location contacts
Contact: Uffici Studi FIL FIL +39 0131 20 ext 6066 segreteria@filinf.it

Locations
Layout table for location information
Italy
A.O S.Orsola-Malpighi Recruiting
Bologna, BO, Italy, 40138
Principal Investigator: Vittorio Stefoni, MD         
Spedali Civili Recruiting
Brescia, BS, Italy, 25123
Principal Investigator: Giuseppe Rossi, MD         
Fondazione IRCCS Milano INT Recruiting
Milano, MI, Italy, 20133
Principal Investigator: Paolo Corradini, Prof.         
AO Niguarda Ca' Granda Not yet recruiting
Milano, MI, Italy, 20162
Principal Investigator: Chiara Rusconi, MD         
Istituto Clinico Humanitas Not yet recruiting
Rozzano, MI, Italy, 20089
Principal Investigator: Armando Santoro, Prof.         
AOU Città della Salute e della Scienza Recruiting
Torino, TO, Italy, 10126
Principal Investigator: Umberto Vitolo, MD         
IRCCS Fondazione Pascale Recruiting
Napoli, Italy, 80131
Principal Investigator: Antonello Pinto, MD         
Sponsors and Collaborators
Fondazione Italiana Linfomi ONLUS
Investigators
Layout table for investigator information
Principal Investigator: Vittorio Stefoni, MD Ematologia "L. & A. Seragnoli" - Policlinico S. Orsola Malpighi

Layout table for additonal information
Responsible Party: Fondazione Italiana Linfomi ONLUS
ClinicalTrials.gov Identifier: NCT02499627     History of Changes
Other Study ID Numbers: FIL-BBV
First Posted: July 16, 2015    Key Record Dates
Last Update Posted: May 1, 2019
Last Verified: April 2019
Keywords provided by Fondazione Italiana Linfomi ONLUS:
Lymphoma
Hodgkin
PTCL
CD30+
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphatic Diseases
Bendamustine Hydrochloride
Antibodies, Monoclonal
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs